IRLAB Therapeutics AB Class A AI Stock Analysis
Want to see SE:IRLAB.A full AI Analyst Report?
IRLAB Therapeutics AB Class A (IRLAB.A) AI Stock Analysis
IRLAB Therapeutics AB Class A
(Nasdaq OMX AB:IRLAB.A)
The stock scores at the absolute bottom of the range, reflecting a convergence of severe risks. The primary driver is a state of financial distress marked by collapsing revenues and massive cash burn that threatens the company's survival. This is reinforced by a bearish technical trend with the stock in a clear downtrend and deeply oversold, alongside a negative P/E ratio that underscores its lack of profitability. The company's low debt is the only minor positive, but it is completely overshadowed by the unsustainable operating model.
IRLAB Therapeutics AB Class A (IRLAB.A) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 126.11M
- Dividend Yield
- ―
- Average Volume (3M)
- 2.52M
- Price to Earnings (P/E)
- -1.7
- Beta (1Y)
- 0.42
- Revenue Growth
- -21.20%
- EPS Growth
- 68.24%
- Country
- Sweden
- Employees
- 31
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
IRLAB Therapeutics AB Class A Business Overview & Revenue Model
Company Description
IRLAB Therapeutics AB (publ) is a pharmaceutical company committed to developing treatments for Parkinson's disease. Its clinical pipeline features Mesdopetam, currently progressing through phase IIb/III studies to address dyskinesia, and Pirepemat,...
How the Company Makes Money
IRLAB Therapeutics primarily generates revenue through collaboration and partnering arrangements for its drug candidates, which can include upfront payments, research funding, development and regulatory milestone payments, and royalties on future net...
IRLAB Therapeutics AB Class A Financial Statement Overview
Summary
Financial health is extremely poor. The company suffers from collapsing revenues, deeply negative margins, and massive, persistent cash burn that is rapidly eroding its equity base. The only mitigating factor is a recently improved, low-debt balance sheet, but this is insufficient to offset the severe operational distress.
Income Statement
8Very NegativeBalance Sheet
35NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 67.42M | 57.46M | 94.63M | 5.68M | 61.14M | 207.78M |
| Gross Profit | -43.72M | -92.35M | -92.42M | -122.73M | -111.23M | 168.69M |
| EBITDA | -39.60M | -88.03M | -68.07M | -173.32M | -109.13M | 56.05M |
| Net Income | -46.76M | -110.01M | -83.13M | -177.84M | -114.20M | 51.78M |
Balance Sheet | ||||||
| Total Assets | 153.86M | 138.21M | 136.21M | 177.12M | 323.56M | 472.45M |
| Cash, Cash Equivalents and Short-Term Investments | 90.64M | 81.86M | 66.92M | 111.31M | 252.78M | 401.90M |
| Total Debt | 17.93M | 29.95M | 60.42M | 27.57M | 3.98M | 6.60M |
| Total Liabilities | 73.70M | 107.49M | 103.58M | 61.36M | 32.72M | 72.97M |
| Stockholders Equity | 80.16M | 30.72M | 32.63M | 115.76M | 290.83M | 399.48M |
Cash Flow | ||||||
| Free Cash Flow | -77.27M | -55.22M | -65.79M | -165.14M | -145.99M | 127.93M |
| Operating Cash Flow | -77.27M | -55.22M | -65.59M | -164.85M | -142.61M | 128.64M |
| Investing Cash Flow | 0 | 0 | -199.00K | -293.00K | -3.38M | -708.00K |
| Financing Cash Flow | 58.00M | 73.41M | 21.40M | 23.68M | -3.13M | -3.04M |
IRLAB Therapeutics AB Class A Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IRLAB.A, the sentiment is Negative. The current price of 0.85 is below the 20-day moving average (MA) of 1.92, below the 50-day MA of 1.86, and below the 200-day MA of 1.55, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 26.87 is Positive, neither overbought nor oversold. The STOCH value of 24.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:IRLAB.A.
IRLAB Therapeutics AB Class A Peers Comparison
Overall Rating
SE:SANION77Outperform
SE:BIOA.B65Neutral
SE:ALZCUR51Neutral
SE:SYNACT43Neutral
SE:IRLAB.A37Underperform
SE:ALZ36Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 77Outperform | SEK 1.64B | 8.89 | 29.71% | ― | 24.98% | -31.44% | |
| 65Neutral | SEK 27.51B | 260.50 | 5.18% | 0.69% | -46.09% | -90.13% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | SEK 882.54M | 10.67 | 105.09% | ― | ― | ― | |
| 43Neutral | SEK 743.15M | -7.07 | -60.58% | ― | ― | 14.35% | |
| 37Underperform | SEK 126.11M | -1.69 | -75.46% | ― | -21.20% | 68.24% | |
| 36Underperform | SEK 100.82M | -1.88 | -15.44% | ― | -100.00% | 40.79% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:IRLAB.A | IRLAB Therapeutics AB Class A | 0.85 | -1.39 | -62.14% | |
| SE:ALZ | Alzinova AB | 0.32 | -1.08 | -77.20% | |
| SE:ALZCUR | AlzeCure Pharma AB | 6.40 | 4.60 | 254.77% | |
| SE:BIOA.B | BioArctic AB Class B | 310.00 | 31.45 | 11.29% | |
| SE:SYNACT | SynAct Pharma AB | 13.22 | -7.18 | -35.20% | |
| SE:SANION | Saniona AB | 11.91 | -4.37 | -26.84% |
IRLAB Therapeutics AB Class A Corporate Events
IRLAB Reports Nine-Month Results and Appoints New Chairman
IRLAB Therapeutics develops Parkinson’s disease drug candidates through its AI-based research platform, ISP, and a broad development portfolio. The company reported net sales of SEK 52,696 thousand for January–September 2026, compared with SEK 42,739...
IRLAB Shifts Focus to Commercializing Existing Drug Portfolio
IRLAB said it is redirecting resources toward revenue-generating partnerships, licensing agreements and divestments involving its existing drug portfolio, while reducing investment in new candidate discovery. The company said the likelihood of signin...
IRLAB Announces Q3 2026 Report Presentation and Webcast
The company will publish its January–September 2026 interim report on November 13 at 07:00 CEST, followed by a Swedish-language webcast featuring its chief executive, research head, and finance chief. The session will provide management commentary an...
IRLAB Wins Key U.S. Patent Boost for Next-Generation Parkinson’s Drug IRL1117
IRLAB Therapeutics AB, a Gothenburg-based biopharmaceutical company listed on Nasdaq Stockholm, specializes in developing new treatments for Parkinson’s disease across all stages of the illness. Built on research from Nobel Laureate Prof. Arvid Carls...
IRLAB names nomination committee ahead of 2027 AGM
IRLAB Therapeutics has appointed a nomination committee for its 2027 annual general meeting, in line with a mandate approved by shareholders in 2024. The committee includes representatives of the three largest shareholder groups as of late August 202...
IRLAB Research on Potential First-in-Class Apathy Drug Linepemat Published
IRLAB Therapeutics said the preclinical research underpinning its investigational drug linepemat, also known as IRL757, has been published in the peer-reviewed journal Bioorganic & Medicinal Chemistry Letters. The molecule was designed to enhance act...
IRLAB to Spotlight Parkinson’s Pipeline at Redeye Neurology Event
IRLAB Therapeutics AB, a Stockholm-listed biopharma group specializing in novel Parkinson’s disease therapies, is advancing multiple candidates including Mesdopetam, which has completed Phase IIb for levodopa-induced dyskinesias and is being prepared...
IRLAB Therapeutics Names Janne Backman as Chairman to Steer Parkinson’s Pipeline and Partnerships
IRLAB Therapeutics AB, a Nasdaq Stockholm-listed biopharmaceutical group based in Gothenburg, develops novel Parkinson’s disease therapies from early research through late-stage clinical trials, leveraging a proprietary systems biology platform to ge...
IRLAB CEO to Step Down in 2027 as Parkinson’s Pipeline Advances
IRLAB Therapeutics’ chief executive Kristina Torfgård has informed the board she intends to step down during the first quarter of 2027, though she will remain in place to ensure a smooth handover while the board launches an immediate search for her s...
IRLAB Therapeutics Updates Share Capital After Completed Rights Issue
IRLAB Therapeutics AB has updated its share capital structure following the completion of a rights issue and an overallotment issue of ordinary shares of series A, resolved by the board in May and approved by an extraordinary general meeting in June...
IRLAB strengthens Parkinson’s pipeline and finances in Q2 2026
IRLAB reported second-quarter 2026 net sales of SEK 6.4 million, down from SEK 19.5 million a year earlier, and an operating loss of SEK 16.7 million, while earnings per share improved to a loss of SEK 0.23 versus SEK 0.62. The company’s rights issue...
IRLAB to Webcast Q2 2026 Interim Report as Parkinson’s Pipeline Advances
IRLAB Therapeutics AB, a Gothenburg-based biotech specializing in novel Parkinson’s disease therapies, is advancing a diversified clinical and preclinical pipeline built on its proprietary systems biology-based research platform. With multiple drug c...
WHO Grants INN Name to IRLAB’s Apathy Drug Candidate Linepemat
IRLAB Therapeutics AB, a Gothenburg-based biopharmaceutical company specializing in Parkinson’s disease and other neurodegenerative disorders, is building a diversified pipeline of small-molecule drug candidates addressing motor complications, falls...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 16, 2026
